文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

() rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights.

作者信息

Nguyen Ha Minh, Le Duong Hoang Huy, Nguyen Thinh Hung, Cao Dinh Hung, Nguyen Tuan Huu Ngoc

机构信息

Biomedical Research Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.

Medical Biochemistry & Molecular Biology Department, Fundamental Sciences and Basic Medical Sciences, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.

出版信息

Clin Exp Gastroenterol. 2025 Aug 29;18:191-204. doi: 10.2147/CEG.S532528. eCollection 2025.


DOI:10.2147/CEG.S532528
PMID:40904834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12404256/
Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is an increasing public health concern in Vietnam, particularly among working-age adults (18-60 years). The rs738409 variant (C>G) is a well-established risk factor for NAFLD globally; however, its impact on the Vietnamese population remains inadequately studied. This study investigates its association with NAFLD risk and its interaction with metabolic factors. METHODS: A case-control study was conducted with 135 NAFLD patients and 270 age- and sex-matched controls, collected from April to August 2023. Hepatic steatosis was evaluated via ultrasound, and NAFLD was diagnosed in cases without excessive alcohol consumption and other liver conditions. Data on demographics, clinical characteristics, and biochemical markers (eg, lipid profiles, liver enzymes) were collected. The rs738409 variant was genotyped using real-time PCR. Statistical methods included Hardy-Weinberg equilibrium testing, allele and genotype frequency comparisons, multivariable logistic regression adjusting for metabolic covariates, and ROC curve analysis to evaluate the predictive accuracy of rs738409. RESULTS: The frequency of the G allele was significantly higher in NAFLD patients (35.93%) compared to controls (28.15%, = 0.024). Individuals with CG+GG genotypes exhibited an increased risk of NAFLD (OR = 1.433, = 0.042), with a stronger association in those with low HDL-c (OR = 2.074, = 0.009). However, multivariable logistic regression analysis indicated that the rs738409 variant was not an independent risk factor for NAFLD in this population, in contrast to obesity and high triglycerides. ROC analysis revealed rs738409 alone had limited predictive power for NAFLD (AUC = 0.5537) but predictive accuracy improved slightly when combined with metabolic factors such as BMI and triglyceride levels (AUC = 0.7840). CONCLUSION: The rs738409 variant modestly increases NAFLD risk in Vietnamese working-age adults, particularly in those with dyslipidemia. However, metabolic factors, such as obesity and lipid disorders, play a more dominant role. This underscores the importance of lifestyle interventions and metabolic control in NAFLD management.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/923e9d3854a8/CEG-18-191-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/ac5a0008ed61/CEG-18-191-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/cb07707a241b/CEG-18-191-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/08117bafc53a/CEG-18-191-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/923e9d3854a8/CEG-18-191-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/ac5a0008ed61/CEG-18-191-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/cb07707a241b/CEG-18-191-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/08117bafc53a/CEG-18-191-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2a/12404256/923e9d3854a8/CEG-18-191-g0004.jpg

相似文献

[1]
() rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights.

Clin Exp Gastroenterol. 2025-8-29

[2]
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content.

Cardiovasc Diabetol. 2023-3-21

[3]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[4]
Nonalcoholic Fatty Liver

2025-1

[5]
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease.

Am J Gastroenterol. 2015-6

[6]
Breaking boundaries: Unraveling metabolic dysfunction-associated steatotic liver disease in children of India and Canada.

Can Liver J. 2024-2-26

[7]
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.

Hepatology. 2011-5-14

[8]
Molecular Characterization of Patatin-Like Phospholipase Domain-Containing 3 (PNPLA3) Gene in Alcoholic Liver Disease.

Cureus. 2025-7-19

[9]
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.

JHEP Rep. 2024-4-6

[10]
PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population.

Ann Hepatol. 2025

本文引用的文献

[1]
Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise.

J Endocr Soc. 2025-6-14

[2]
Global, regional, and national burden of NAFLD in youths and young adults aged 15-39 years, 1990-2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021.

Front Nutr. 2025-1-28

[3]
Epidemiology of metabolic dysfunction-associated steatotic liver disease.

Clin Mol Hepatol. 2025-2

[4]
The burden of non-alcoholic fatty liver disease among working-age people in the Western Pacific Region, 1990-2019: an age-period-cohort analysis of the Global Burden of Disease study.

BMC Public Health. 2024-7-11

[5]
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.

Hepatol Int. 2024-8

[6]
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.

Clin Gastroenterol Hepatol. 2024-10

[7]
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Clin Mol Hepatol. 2024-4

[8]
Prevalence of metabolic syndrome among Vietnamese adult employees.

Nutr Metab Cardiovasc Dis. 2024-2

[9]
Diagnosis and Management of Nonalcoholic Fatty Liver Disease.

JAMA. 2023-11-7

[10]
Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).

Mol Metab. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索